Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ginseng focus trial halted early – little to go on

NCT ID NCT07255755

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single 200 mg dose of American Ginseng (Cereboost) could improve attention and brain function in healthy young adults aged 18-40. Participants completed cognitive tests and gave blood samples over 6 hours. However, the trial was terminated early and only enrolled 27 people, so no reliable conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
American Ginseng extract (Cereboost)
What this could lead to
If it worked, this could suggest a natural supplement for short-term attention or focus in healthy people.
What could go wrong
The trial was terminated early with only 27 participants, so results are incomplete and unreliable. Any benefits would be small and temporary, not a treatment for any condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

27 people

The number who actually took part.

Started

Dec 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To be eligible for inclusion, the Participant must fulfil all the following criteria: 1. Be able to give written informed consent. 2. Be between 18-40 years, inclusive. 3. Depression Anxiety and Stress Scale scores (DASS-21): 1. Depression ≤9 2. Anxiety ≤7 3. Stress ≤14 4. Willing to refrain from alcohol consumption 24-hours prior to assessment visits. 5. Willing to refrain from caffeine consumption (including but not limited to energy drinks, soda, coffee…) on the morning of the assessment visit. 6. Non-smokers and non-vapers 7. Willing to consume the Study Product (SP). 8. Willing to attend the study visit in an overnight fasted state, having followed a low-polyphenol diet for 48 h. 9. Fluent in written and spoken English Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: 1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding. 2. Has food allergies or other issues with foods that would preclude intake of the Study Products. 3. Not willing to consume gelatine from bovine/porcine source 4. Has a BMI ≤18.5 or ≥30kg/m2 5. Blood pressure \>140/90 mmHg 6. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. 7. Excluded health conditions include: 1. Cognitive disorders in the past 12 months. 2. Current or past history of a major neuropsychiatric disorder, including: bipolar disorder, schizophrenia and schizotypal personality disorder 3. Current or past history of a major neurological condition. 4. Gastrointestinal disorders (e.g. IBS/IBD) 5. ADHD (attention deficit hyperactivity disorder) 6. Learning disabilities and difficulties 7. Current, uncorrected, vision or hearing impairment 8. Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include: 1. Anti-psychotics 2. Anti-coagulants (including Warfarin) 3. Anti-platelets (including Aspirin and Clopidogrel) 4. Sedatives 5. Monoamine Oxidase Inhibitors (MAOIs) 9. Taking any dietary supplements and unwilling to stop for two weeks prior to and for the duration of participation in the study 10. Current or history of drug or alcohol abuse 11. Current or history of: HIV, kidney disease, liver or biliary disorders, cancer, cardiovascular disease, pulmonary disease (chronic respiratory trouble) 12. Planned surgery within 2 weeks of their participation in the study 13. Do not agree to the GP being contacted about participation and screening results 14. Participated in any other cognitive trials within the last month

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Quadram Insitute Clinical Research Facility

    Norwich, Norfolk, NR4 7UQ, United Kingdom

  • University of East Anglia

    Norwich, Norfolk, NR4 7UQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.